NCT06099743 ASCENT Intervention for Brain Tumor Patients
| NCT ID | NCT06099743 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Malignant Brain Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-05-15 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-05-15 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to refine and test a psychosocial intervention called ASCENT (ACT-based Supportive intervention for patients with CENTral nervous system tumors). This intervention was developed to help patients after being diagnosed with a brain tumor. The main question this study aims to answer is whether this intervention is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in 6 coaching sessions and complete short surveys at four different time points. Some participants will be asked to share feedback via interviews.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Massachusetts General Hospital Cancer Center Patient * Within 6 months of diagnosis of malignant primary Central Nervous System (CNS) tumor * English speaking Exclusion Criteria: * Inability to provide informed consent as assessed by the study team (e.g., due to severe cognitive impairment/dementia) * Moderate to severe receptive aphasia (Quick Aphasia Battery sentence comprehension subscale \< 8) * Current or imminent hospice enrollment
Contact & Investigator
Deborah A Forst, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06099743 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Brain Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06099743 currently recruiting?
Yes, NCT06099743 is actively recruiting participants. Contact the research team at dforst@mgb.org for enrollment information.
Where is the NCT06099743 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06099743 clinical trial?
NCT06099743 is sponsored by Massachusetts General Hospital. The principal investigator is Deborah A Forst, MD at Massachusetts General Hospital. The trial plans to enroll 100 participants.